

Press Release

New inhaled therapies for viral infections

Activoris and CytoTools agree on strategic collaboration for respiratory treatments against diseases like COVID-19 and Influenza

Gemünden (Germany), May 27, 2021 – Germany-based Activoris Medizintechnik GmbH today announced the collaboration with CytoTools AG (ISIN DE000A0KFRJ1). The listed company from Darmstadt published a corresponding announcement on April 26, 2021.

The aim of the cooperation is to introduce the virtually side-effect-free active ingredient DPOCL, which has been shown to be extremely effective in other indications, directly into the lungs in an inhaled therapy approach. The project is to be rapidly brought to a licensable stage as part of the collaboration. The next steps will include first performing an aerosol characterization to determine the optimal inhalation device, and an ADME-Tox to investigate effects of inhaled administration of DPOCL as an aerosol within the organism.

Activoris will be supported by its long-term collaboration partners Actarmo Medical GmbH (www.actarmo.com, GMP and CMC services) and ACLiRA Consulting GmbH (www.aclira.com, scientific and regulatory strategy).

"These results will form the basis for being able to investigate the effectiveness of the therapy within a first patient study," explains Dr. Dirk Kaiser, Chief Research & Development Officer at CytoTools. Axel Fischer, CEO at Activoris added: „We are very excited about the collaboration with CytoTools, to which we bring over 20 years of inhalation technology experience and a proven exit track record. With DPOCL, CytoTools has an active compound in its portfolio that seems predestined for the inhaled approach."

About Activoris Medizintechnik GmbH

Activoris Medizintechnik GmbH in Gemünden (Germany) is a specialized MedTech and pharmaceutical service provider with particular expertise in respiratory therapies and inhalation. Its customers are established companies as well as innovative startups from the biotech, medtech and pharma industries, which achieve greater flexibility, cost efficiency and faster market access through Activoris' outsourcing services. Activoris operates sites in Gemünden (Wohra), Munich and Schwamstadt.

Contact: Activoris Medizintechnik GmbH
Axel Fischer
Wohraer Str. 37

35285 Gemünden (Wohra)
Tel. +49 (0) 6453.58535.10
axel.fischer@activoris.com
www.medtech.activoris.com

About CytoTools AG

CytoTools AG is a German biotechnology holding company that translates results from basic cell biology research on cell growth and programmed cell death into novel therapies for causal disease treatment and cure. CytoTools' versatile product pipeline includes proprietary chemical compounds and biopharmaceuticals that have the potential to provide new treatment options in dermatology, cardiology, urology and oncology. CytoTools is structured as a technology holding and investment company and holds interests in its subsidiaries DermaTools Biotech GmbH (65%) and CytoPharma GmbH (50%).

Contact: CytoTools AG
 Ingo Middelmanne
 Investor Relations
 Mobil +49-174-9091190
 E-Mail: middelmenne@cytotools.de